TNF inhibitor

      RT @drdavidliew: ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs.

      What about in real-wor

      David Liew drdavidliew

      3 years 10 months ago
      ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs. What about in real-world data? Looking at CorEvitas, less so LDA: aOR 0.99 MCID in CDAI: 1.06 Even without MTX, both great drug classes for RA Equally so? #ACR21 ABST0834 @RheumNow https://t.co/6wvzVrXTW6 https://t.co/fYEktJhZuV
      RT @drdavidliew: In Australia, there's free choice of originator vs biosimilar for etanercept.

      Real-world data shows ex

      David Liew drdavidliew

      3 years 10 months ago
      In Australia, there's free choice of originator vs biosimilar for etanercept. Real-world data shows exactly what you'd expect over >48 months - and sometimes it's what you expect that's exactly what you want to see... OPAL data #ACR21 0840 @RheumNow https://t.co/YJA2Cua9cw
      Perspectives on TNFi: Dr. Jon Giles
      3 years 10 months ago
      RT @ericdeinmd: #ACR21 Abst#0910 by @rheum_cat. Do TNFi ⬆️ risk of incident HTN in AxSpa?
      ⭐️PSOAS cohort: Prosp

      Eric Dein ericdeinmd

      3 years 10 months ago
      #ACR21 Abst#0910 by @rheum_cat. Do TNFi ⬆️ risk of incident HTN in AxSpa? ⭐️PSOAS cohort: Prosp study from 2003-2018 ▶️When adjusted for confounders (obesity, disease activity, NSAID use), insufficient evidence to show ⬆️ risk of HTN w TNFi https://t.co/DCZ3W8CkOa @Rheumnow
      RT @AurelieRheumo: TNFi + JIA = watch the skin! A nearly 3fold increase of paradoxal psoriasis in JIA patients exposed t

      Aurelie Najm AurelieRheumo

      3 years 10 months ago
      TNFi + JIA = watch the skin! A nearly 3fold increase of paradoxal psoriasis in JIA patients exposed to TNFi reported in the CARRA registry w/ incidence rate the highest on children receiving adalimumab. #Abst0241 @RheumNow #ACR2021 https://t.co/uXOwV2RlGu https://t.co/8f8mvVUkV2
      RT @KDAO2011: ⁦@JointMD⁩ shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. ⁦@RheumNowâ

      TheDaoIndex KDAO2011

      3 years 10 months ago
      ⁦@JointMD⁩ shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. ⁦@RheumNow⁩ #acr21 https://t.co/mVw05iFPhF
      acr_session2.jpeg
      Opening Day Report
      3 years 10 months ago
      The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford). The Year in Review featured a clinical vs basic science Brigham and Women’s Hospital faceoff between its two faculty, Dr. Karen Costenbader and Dr. Michael Brenner.
      Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan
      3 years 10 months ago
      RT @doctorRBC: 2 year study of AxSpA pts in clinical remission who tapered TNFi.
      ⭐️52% successfully tapered to eithe

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      2 year study of AxSpA pts in clinical remission who tapered TNFi. ⭐️52% successfully tapered to either 2/3, 1/2 or 1/3 dose ⭐️Baseline physician global score independent predictor of successful tapering Abs#364 #ACR21 @RheumNow https://t.co/9Kti5JGMYr https://t.co/y1Uj2dTABC
      RT @ERheumat: #ACR21 #ACR2021
      Rheumatology Reproductive Health
      👉🏻 Biologics and breast milk
      👉🏻 Good vaccine

      EnvisionRheumat ERheumat

      3 years 10 months ago
      #ACR21 #ACR2021 Rheumatology Reproductive Health 👉🏻 Biologics and breast milk 👉🏻 Good vaccine response with TNFi (like with covid vaccines ) 👉🏻 ustekimumab seems safe in pregnancy 👉🏻 Tofacitinib/ small molecules may cross placenta/ be in breast milk ➡️ contraindicated in preg/BF https://t.co/qk3sLR4QHz
      RT @AkhilSoodMD: Abs 0463 #ACR21 @RheumNow
      Park & colleagues compared treatment persistence across abatacept, TNFi,

      Akhil Sood MD AkhilSoodMD

      3 years 10 months ago
      Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database - Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq
      RT @Janetbirdope: #ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#

      Janet Pope Janetbirdope

      3 years 10 months ago
      #ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#0463 @RheumNow Adjusting for confounding incl line of Rx / past bio Rx, #abatacept wins. But data not stratified for bio naive or exposed. Not sure if that would alter results https://t.co/1dEQncwPQF
      RT @AurelieRheumo: We should aim for early treatment and good retention in ax-SpA to prevent structural evolution. >

      Aurelie Najm AurelieRheumo

      3 years 10 months ago
      We should aim for early treatment and good retention in ax-SpA to prevent structural evolution. >12 months of TNFi treatment in the previous 2 years associated w/ ⬇️ radiographic progression of SIJ in r- and nr-axSpA in GESPIC, #Abst0174 @RheumNow #ACR21 https://t.co/2V1q4dUwFO https://t.co/lxQU4zAP1I
      RT @uptoTate: Danish axSpA study shows pts in remission on TNFi may be able to taper and remain in remission at the 2 ye

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Danish axSpA study shows pts in remission on TNFi may be able to taper and remain in remission at the 2 year mark. Abs0364 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/LBR5cSThQY https://t.co/sCqqhuBaTS
      RT @KDAO2011: Experts (Drs. M Clowse, Sammaratino) limit mAb TNFi 1 month b/f delivery or extend dosing. But, they do do

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Experts (Drs. M Clowse, Sammaratino) limit mAb TNFi 1 month b/f delivery or extend dosing. But, they do dose again for flares. Risk for infection is low based on the PIANO registry. Postpartum, they restart the meds w/in 1 week (vag delivery), 2 weeks C/S @rheumnow #pregnancy
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Catch up on Conference Podcasts

      ×